AY
Alethia Young Cantor Fitzgerald Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Regeneron Pharmaceuticals
REGN
$59.2B
| $556.53 | $850 |
53%
upside
| Neutral |
16 Oct ‘23
1 year ago |
|
2
ALX Oncology
ALXO
$59.4M
| $1.09 | $18 |
1,551%
upside
| Overweight |
12 Sep ‘23
2 years ago |
|
3
Curis
CRIS
$21.4M
| $1.81 | $60 |
3,215%
upside
| Overweight |
7 Sep ‘23
2 years ago |
|
4
Eledon Pharmaceuticals
ELDN
$154M
| $2.68 | $9 |
236%
upside
| Overweight |
22 Aug ‘23
2 years ago |
|
5
Verastem
VSTM
$630M
| $9.92 | $34 |
243%
upside
| Overweight |
6 Jul ‘23
2 years ago |
|
6
Biogen
BIIB
$20.7B
| $143.60 | $327 |
128%
upside
| Neutral |
15 Oct ‘21
3 years ago |
|
7
Adverum Biotechnologies
ADVM
$74.3M
| $3.47 | $30 |
765%
upside
| Neutral |
23 Jul ‘21
4 years ago |
|
8
RAPT Therapeutics
RAPT
$220M
| $13.60 | $568 |
4,076%
upside
| Overweight |
14 Jun ‘21
4 years ago |
|
9
Vertex Pharmaceuticals
VRTX
$101B
| $396.48 | $281 |
29%
downside
| Overweight |
11 Jun ‘21
4 years ago |
|
10
Akebia Therapeutics
AKBA
$830M
| $3 | $8 |
167%
upside
| Overweight |
8 Mar ‘21
4 years ago |
|
11
Fate Therapeutics
FATE
$111M
| $0.9799 | $98 |
9,901%
upside
| Overweight |
25 Feb ‘21
4 years ago |
|
12
Amgen
AMGN
$151B
| $279.97 | $295 |
5%
upside
| Overweight |
3 Feb ‘21
4 years ago |
|
13
Gilead Sciences
GILD
$144B
| $115.76 | $86 |
26%
downside
| Overweight |
29 Oct ‘20
4 years ago |
|
14
TG Therapeutics
TGTX
$5.14B
| $32 | $48 |
50%
upside
| Overweight |
28 Oct ‘20
4 years ago |
|
|
BCYC
15
Bicycle Therapeutics
BCYC
$485M
| $7.12 | $30 |
321%
upside
| Overweight |
12 Oct ‘20
4 years ago |
|
16
Agios Pharmaceuticals
AGIO
$2.12B
| $36.15 | $72 |
99%
upside
| Overweight |
31 Jul ‘20
5 years ago |
|
17
Pacific Biosciences
PACB
$375M
| $1.31 | $5 |
282%
upside
| Overweight |
2 Jun ‘20
5 years ago |
|
18
Incyte
INCY
$16.9B
| $85.60 | $100 |
17%
upside
| Neutral |
19 May ‘20
5 years ago |
|
19
Ascendis Pharma
ASND
$12.4B
| $202.91 | $201 |
1%
downside
| Overweight |
20 Apr ‘20
5 years ago |
|
20
PTC Therapeutics
PTCT
$4.52B
| $58.42 | $85 |
46%
upside
| Overweight |
8 Apr ‘20
5 years ago |
|
21
Aurinia Pharmaceuticals
AUPH
$1.62B
| $12.35 | $32 |
159%
upside
| Overweight |
6 Mar ‘20
5 years ago |
|
22
Sarepta Therapeutics
SRPT
$1.84B
| $17.64 | $217 |
1,130%
upside
| Overweight |
27 Feb ‘20
5 years ago |
|